

RESEARCH & DEVELOPMENT: Pioneering medical science

Wockhardt is among the few Indian companies to have built a strong research capability. Over time, it has made vast investments in multi-disciplinary, multi-location R&D programmes. The company's determination to retain its position as a leading researcher underpins its future growth.

Innovating through R&D

Innovation is the cornerstone of Wockhardt's business. Its research encompasses pharmaceutical formulations, biopharmaceutical bulk and formulations for recombinant products, novel drug delivery systems as well as process engineering for Active Pharmaceutical Ingredients (API) and new chemical entities under the new drug discovery programme.

Pioneering biotechnology research

Wockhardt made its mark in India through pioneering research in biotechnology. It was the first Indian company, and fourth in the world, to have developed from concept to market stage its own version of recombinant human insulin – Wosulin. 2009 saw Wockhardt's launch, in India, of a biotechnology driven long-acting insulin analogue glargine, under the brand name Glaritus.

Wockhardt is only the second company in the world, after the originator, to have developed this. Now diabetics in India have access to affordable medication and treatment. Wockhardt has also developed

its innovative disposable pen delivery device that has been granted a global patent.

With this basket of recombinant brands, Wockhardt is making its initial foray into 20 less-regulated regions such as Latin America and Africa. The company is also progressing its clinical trials to meet the regulatory requirements of some developed countries creating a springboard for future business opportunities.

Wockhardt API research has developed the skills to create a wide range of complex and multi-step APIs for the in-house ANDA programme. Wockhardt has gained approvals for more than 47 US Drug Master Files (DMF), 10 Certificate of Suitability of European Pharmacopoeia (CEP) and seven Active Substance Master Files (ASMF).

ANDAs offer platform for growth

Wockhardt invests in R&D in the development of products for its Abbreviated New Drug Applications (ANDAs) filings for the US and European markets. This is making great inroads with 87 products from Wockhardt US and MGP operational in the US market and 23 in the EU. Wockhardt USA launched 'Day-1' in 2009, for Off-Patent products Divalproex Sodium ER Tablets 250mg/500mg and Nifedipine Injection 2.5mg/ml. Venlafaxine Retard Tablets were launched in the EU. The company selects complex high technology products

for ANDA approvals, an important growth driver for the US and European markets.

New drug discovery programme

The new drug discovery programme of anti-infectives has made progress at various stages of pre-clinical and clinical trials of its lead molecules WCK2349, WCK4873, WCK4086 and WCK771.

Novel drug delivery systems

Wockhardt has developed several products based on innovative drug delivery systems and brought them to the Indian market.

The technology enhances release patterns and effectiveness, and encourages patient compliance. The most significant of these is the development of the high blood pressure drug Metoprolol which offers 24-hour extended release in tablet form. This is the second generic product, after the originator's, whose ANDA has received US FDA approval.

Government award

Another indicator of Wockhardt's determination to succeed in the global market is its pipeline of patents. The company has to date filed 1,246 patents with 74 granted.

Wockhardt was awarded the prestigious Patent Award by the Indian Government for the maximum number of patent filings and grants from India.



'2009 saw Wockhardt's launch, in India, of a biotechnology driven long-acting insulin analogue glargine, under the brand name Glaritus. Wockhardt is only the second company in the world, after the originator, to have developed this'

